Dendreon Corporation (NASDAQ:DNDN) has announced that the underwriters of its most recent public offering has exercised their option to purchase 2,250,000 shares of common stock at a price of $24.75 per share. The exercise of the option increased the size of the offering to 17,250,000 shares of common stock. The company’s net proceeds are expected to be $409.5 million after deducting the underwriting commissions.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
A biotechnology company, Dendreon is engaged in the discovery, development and commercialization of therapeutics to improve cancer treatment options for patients. Its most advanced product candidate is Provenge. Provenge is an active cellular immunotherapy.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
